SEC Form 4 · accession 0001193125-26-374607
CORCEPT THERAPEUTICS INC · CORT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Kimberly Park
Director
Period of report
Aug 26, 2026
Accepted (ET)
Aug 28, 2026 · 4:30 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001088856
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Aug 26, 2026 | M | 30,000 | $13.49 | A | 30,000 | D | |
| Common Stock | Aug 26, 2026 | F | 3,315 | $122.09 | D | 26,685 | D | |
| Common StockF2 | Aug 26, 2026 | S | 26,685 | $122.5471 | D | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F3 | $13.49 | Aug 26, 2026 | M | 30,000 | D | — | Sep 17, 2029 | Common Stock | 30,000 | 30,000 | D |
Explanation of responses
- F1These shares were withheld by the Issuer in order to cover the exercise price in connection with the net exercise of stock options reported herein.
- F2Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $122.50 to $122.80 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
- F3Fully exercisable.
Remarks
The power of attorney under which this form was signed is on file with the Commission.